6815 Stock Overview
Researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Diamond Biotechnology Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$71.90 |
| 52 Week High | NT$113.95 |
| 52 Week Low | NT$59.00 |
| Beta | 0.38 |
| 11 Month Change | -8.64% |
| 3 Month Change | -20.73% |
| 1 Year Change | -8.84% |
| 33 Year Change | 207.96% |
| 5 Year Change | n/a |
| Change since IPO | 32.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6815 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -5.6% | 0.5% | 0.8% |
| 1Y | -8.8% | 0.7% | 30.3% |
Return vs Industry: 6815 underperformed the TW Medical Equipment industry which returned 0.7% over the past year.
Return vs Market: 6815 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6815 volatility | |
|---|---|
| 6815 Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6815 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6815's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | n/a | www.diamond-biotechnology.cc |
Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment.
Diamond Biotechnology Co., Ltd Fundamentals Summary
| 6815 fundamental statistics | |
|---|---|
| Market cap | NT$2.43b |
| Earnings (TTM) | NT$66.97m |
| Revenue (TTM) | NT$707.54m |
36.3x
P/E Ratio3.4x
P/S RatioIs 6815 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6815 income statement (TTM) | |
|---|---|
| Revenue | NT$707.54m |
| Cost of Revenue | NT$372.36m |
| Gross Profit | NT$335.17m |
| Other Expenses | NT$268.21m |
| Earnings | NT$66.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.98 |
| Gross Margin | 47.37% |
| Net Profit Margin | 9.46% |
| Debt/Equity Ratio | 49.3% |
How did 6815 perform over the long term?
See historical performance and comparison